Astrotactin1-based compositions and pharmaceutical formulations
US11396542B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 21, 2019 |
| Grant date | Jul 26, 2022 |
| Priority date | — |
| Expiry date | Aug 21, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2835
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of detecting, preventing, treating, controlling or managing progressive neurodegenerative diseases are provided. These methods comprise the administration of antibodies that reduce or eliminate monocytes that abnormally express Astrotactin (ASTN1), or block blood monocytes that abnormally express ASTN1 from migrating to the central nervous system. Also provided are pharmaceutical compositions that comprise antibodies that specifically target the extracellular domain (ECD2) of ASTN1 for the prevention, treatment, control or management of progressive neurodegenerative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.